Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Free Cash Flow (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Free Cash Flow for 16 consecutive years, with -$234340.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 521.06% year-over-year to -$234340.0, compared with a TTM value of $122692.0 through Sep 2025, up 116.98%, and an annual FY2024 reading of -$538411.0, up 24.3% over the prior year.
  • Free Cash Flow was -$234340.0 for Q3 2025 at China Pharma Holdings, down from $287887.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $939831.0 in Q3 2023 and bottomed at -$1.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$145710.9, with a median of -$116146.0 recorded in 2025.
  • The sharpest move saw Free Cash Flow soared 2911.59% in 2023, then tumbled 521.06% in 2025.
  • Year by year, Free Cash Flow stood at -$205168.0 in 2021, then soared by 398.22% to $611862.0 in 2022, then plummeted by 104.39% to -$26850.0 in 2023, then surged by 790.1% to $185291.0 in 2024, then plummeted by 226.47% to -$234340.0 in 2025.
  • Business Quant data shows Free Cash Flow for CPHI at -$234340.0 in Q3 2025, $287887.0 in Q2 2025, and -$116146.0 in Q1 2025.